TR199900730T2 - S�v� alendronate form�lasyonlar� - Google Patents

S�v� alendronate form�lasyonlar�

Info

Publication number
TR199900730T2
TR199900730T2 TR1999/00730T TR9900730T TR199900730T2 TR 199900730 T2 TR199900730 T2 TR 199900730T2 TR 1999/00730 T TR1999/00730 T TR 1999/00730T TR 9900730 T TR9900730 T TR 9900730T TR 199900730 T2 TR199900730 T2 TR 199900730T2
Authority
TR
Turkey
Prior art keywords
lasyonlar
alendronate
formulation
hcl
pharmaceutically acceptable
Prior art date
Application number
TR1999/00730T
Other languages
Turkish (tr)
Inventor
J. Nerurkar Maneesh
H. Hunke William
Ostovic Drazen
Original Assignee
Merck & Co., Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9700541.7A external-priority patent/GB9700541D0/en
Application filed by Merck & Co., Inc filed Critical Merck & Co., Inc
Publication of TR199900730T2 publication Critical patent/TR199900730T2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Abstract

Alendronik asit veya farmasötik olarak kabul edilebilir bir tuzunun bir sivi formülasyonu olup, bu formülasyonun pH degeri 4-7.5 olacak ve bu formülasyonun 15 ml si 50 ml 0.1N HCI nin pH degerini 1'den 3'e ve tercihen 4'e yükseltilecek kadar tampon içerir.A liquid formulation of alendronic acid or a pharmaceutically acceptable salt of which the pH of the formulation will be 4-7.5, and 15 ml of this formulation buffer enough to increase the pH of 50 ml 0.1N HCl from 1 to 3 and preferably 4. It contains.

TR1999/00730T 1996-10-04 1997-10-02 S�v� alendronate form�lasyonlar� TR199900730T2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2676596P 1996-10-04 1996-10-04
GBGB9700541.7A GB9700541D0 (en) 1997-01-13 1997-01-13 Liquid alendronate formulation
US3600297P 1997-01-22 1997-01-22

Publications (1)

Publication Number Publication Date
TR199900730T2 true TR199900730T2 (en) 1999-07-21

Family

ID=27268667

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1999/00730T TR199900730T2 (en) 1996-10-04 1997-10-02 S�v� alendronate form�lasyonlar�

Country Status (20)

Country Link
EP (1) EP1007054A4 (en)
JP (1) JP2001501222A (en)
CN (1) CN1238691A (en)
AU (1) AU723357B2 (en)
BG (1) BG103306A (en)
BR (1) BR9712197A (en)
CA (1) CA2267370A1 (en)
CZ (1) CZ116999A3 (en)
EA (1) EA001213B1 (en)
EE (1) EE03669B1 (en)
HU (1) HUP0000125A3 (en)
IL (1) IL129127A0 (en)
IS (1) IS5012A (en)
NO (1) NO991569L (en)
NZ (1) NZ334836A (en)
PL (1) PL332496A1 (en)
SK (1) SK42999A3 (en)
TR (1) TR199900730T2 (en)
WO (1) WO1998014196A1 (en)
YU (1) YU17499A (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560490B2 (en) * 2001-01-23 2009-07-14 Gador S.A. Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition and use thereof
US7645460B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of risedronate
US20080287400A1 (en) 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US20080286359A1 (en) 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US7645459B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
US7473684B2 (en) 2005-09-16 2009-01-06 Selamine Limited Bisphosphonate formulation
JP2009508834A (en) * 2005-09-16 2009-03-05 セラマイン リミテッド Bisphosphonate formulation
JP2010043119A (en) * 2009-10-16 2010-02-25 Gador Sa Composition for preventing and/or treating bone metabolic disease, method of preparing the same and use thereof
US8568747B1 (en) 2012-10-05 2013-10-29 Silvergate Pharmaceuticals, Inc. Enalapril compositions
US9463183B1 (en) 2015-10-30 2016-10-11 Silvergate Pharmaceuticals, Inc. Lisinopril formulations
US9669008B1 (en) 2016-03-18 2017-06-06 Silvergate Pharmaceuticals, Inc. Enalapril formulations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4206209A (en) * 1978-11-02 1980-06-03 Kracauer Paul Sublingual aspirin tablet
IT1201087B (en) * 1982-04-15 1989-01-27 Gentili Ist Spa PHARMACOLOGICALLY ACTIVE BIPPHOSPHONES, PROCEDURE FOR THEIR PREPARATION AND RELATED PHARMACEUTICAL COMPOSITIONS
US4922007A (en) * 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
US5019651A (en) * 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
US5270365A (en) * 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
FR2703590B1 (en) * 1993-04-05 1995-06-30 Sanofi Elf USE OF BISPHOSPHONIC ACID DERIVATIVES FOR THE PREPARATION OF MEDICINES FOR PROMOTING BONE REPAIR.
US5510517A (en) * 1993-08-25 1996-04-23 Merck & Co., Inc. Process for producing N-amino-1-hydroxy-alkylidene-1,1-bisphosphonic acids
US5462932A (en) * 1994-05-17 1995-10-31 Merck & Co., Inc. Oral liquid alendronate formulations
US5780455A (en) * 1994-08-24 1998-07-14 Merck & Co., Inc. Intravenous alendronate formulations
US5616571A (en) * 1995-06-06 1997-04-01 Merck & Co., Inc. Bisphosphonates prevent bone loss associated with immunosuppressive therapy

Also Published As

Publication number Publication date
HUP0000125A3 (en) 2001-04-28
CN1238691A (en) 1999-12-15
WO1998014196A1 (en) 1998-04-09
CZ116999A3 (en) 1999-09-15
YU17499A (en) 1999-11-22
HUP0000125A2 (en) 2000-06-28
SK42999A3 (en) 2000-01-18
EP1007054A1 (en) 2000-06-14
BG103306A (en) 2000-01-31
PL332496A1 (en) 1999-09-13
IL129127A0 (en) 2000-02-17
AU723357B2 (en) 2000-08-24
CA2267370A1 (en) 1998-04-09
AU4644897A (en) 1998-04-24
BR9712197A (en) 1999-08-31
JP2001501222A (en) 2001-01-30
NZ334836A (en) 2000-11-24
NO991569L (en) 1999-06-04
IS5012A (en) 1999-03-26
EA199900352A1 (en) 1999-08-26
EE9900113A (en) 1999-10-15
NO991569D0 (en) 1999-03-30
EP1007054A4 (en) 2000-07-19
EA001213B1 (en) 2000-12-25
EE03669B1 (en) 2002-04-15

Similar Documents

Publication Publication Date Title
HUP0203028A2 (en) Pharmaceutical formulation containing tolterodine and its use
TR200101499T1 (en) Azepinoindole derivatives, their preparation and uses.
BR0116452A (en) Compound, pharmaceutical composition, use of a compound
TR200401871T4 (en) Preparation of modified octanoyl amides (octanoyl amides)
DK1200418T3 (en) Nematodicidal trifluorobutene
TR200200579T2 (en) Amino-thyrazolpyridine derivatives.
ATE435648T1 (en) DERIVATIVES OF NODULISPOR ACID
ATE425253T1 (en) TRIBONECTINS
HRP20020198B1 (en) Moxifloxacin formulation containing common salt
DE50004334D1 (en) DESODORIOUS PREPARATIONS CONTAINING WATER-SOLUBLE - (1,3) -GLUCANE
TR199900730T2 (en) S�v� alendronate form�lasyonlar�
RS50089B (en) Ziprasidone suspension
HUP0001014A2 (en) Use of gastrointestinal lipase inhibitors
BR9909357A (en) Mirtazapine solution or suspension mixed with water, pharmaceutical formulation comprising mirtazapine, and use of mirtazapine
SE0004710L (en) System and procedure
ATE201680T1 (en) 2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE ACID ADDITION SALTS
HUP0202729A2 (en) Compositions for parenteral use of estramustine phosphate and amino acids
PT1107793E (en) DEXTRANE-LEPTIN CONJUGATES, PHARMACEUTICAL COMPOSITIONS AND RELATED PROCESSES
UY27373A1 (en) BETA-HUMAN INTERFER FORMULATIONS
DE69936052D1 (en) N1 MODIFIED GLYCOPEPTIDE
MXPA03008837A (en) A stable pharmaceutical composition of pravastatin.
YU87501A (en) Pharmaceutical complex
ATE305517T1 (en) NEUROTRYPSIN
TNSN97173A1 (en) PEPTIDE ANALOGS OF LH-RH, THEIR USES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME.
BG103859A (en) The use of 1-ar(alk)yl-imidazolin-2-on for the treatment of fear and stress conditions